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REVISTA BRASILEIRA DE
REUMATOLOGIA
ditorial
irect  oral  anticoagulants  in antiphospholipid
yndrome
nticoagulantes  orais  diretos  na  síndrome  antifosfolípidentiphospholipid syndrome (APS) is an acquired throm-
ophilia characterized by thrombosis and/or fetal loss asso-
iated or not with the presence of thrombocytopenia in the
resence of circulating antiphospholipid antibodies (anticar-
iolipin, lupus anticoagulant and/or anti-beta2-glycoprotein
). Chronic current treatment of this disease includes the
se of vitamin K antagonist oral anticoagulants. There is a
ood response to treatment with oral anticoagulants; this
herapy aims at preventing new thrombotic events; however,
e-thrombosis rates of 16% covering a time span of 10 years
ere described.1 In this review, the authors found a high
ate of re-thrombosis in triple-positive (anticardiolipin, lupus
nticoagulant and anti-beta2-glycoprotein I) patients (44% in
0 years). However, these medications are associated with
arious drug interactions and are greatly inﬂuenced by the
ietary vitamin K intake.2 It is important that adjustments
nd maintenance controls are carried out, based on prothrom-
in time (through control of the international normalization
atio – INR) regularly performed throughout the life of the
atient, which reduces his/her therapeutic adherence. More-
ver, in some cases, the lupus anticoagulant can change the
rothrombin time and compromise the patient’s monitoring.
nother disadvantage is the decrease in C and S proteins,
hich are natural anticoagulants, with a possible increased
isk of thrombosis in the acute phase of anticoagulation.3
Hence, a new class of oral anticoagulant drugs (direct oral
nticoagulants) emerged, with the advantage of not requiring
 laboratory control, with the added beneﬁt of being very little
nﬂuenced from food and other medications. Examples of such
rugs are dabigatran, which is a direct thrombin inhibitor,
nd rivaroxaban, apixaban, and edoxaban, which are factor
a inhibitors. Such drugs are approved by the FDA for use in
enous thromboembolic events and in cases of atrial ﬁbril-
ation in the general population. There are few reports and
tudies on the use of these medications in patients with APS.Table 1 summarizes the studies with dabigatran or rivaroxa-
ban in APS.
In the literature, about 85 cases of patients with APS who
have taken the new oral anticoagulants were found. Most
of these papers are case reports or series of cases, besides
two retrospective studies and one prospective study. The
median follow-up time ranged from 10 to 19 months and the
most widely used medication was rivaroxaban. The recur-
rence ranged from 0 to 17%, including several arterial events,
when only studies that reported the number of recurrences
in relation to the number of patients at risk who  were fol-
lowed for a period of time were evaluated. The vast majority
of patients included in all studies had suffered previous arte-
rial events or multiple recurrences in the presence of vitamin
K antagonists, or discontinued the use of the anticoagu-
lant, or, ultimately, were triple-positive for antiphospholipid
antibodies.4–9
Two prospective randomized studies, one of Italian origin
(TRAPS) and another English (RAPS),3 currently in a follow-up
phase of patients with APS, with a group treated with warfarin
versus rivaroxaban, were published. These studies will provide
the answers to this question.
Currently, based on available studies and also based on
experts opinion of on the subject, one should contraindicate
the use of these new oral anticoagulants in patients with
triple-positivity of antiphospholipid antibodies, in patients
with a history of arterial events, and with recurring events.
The opinion of experts in this ﬁeld is that vitamin K antago-
nists should remain the basis of anticoagulation in patients
with APS; direct oral anticoagulants may be considered in the
treatment of APS [the ﬁrst venous event], if there is refrac-
toriness, allergy or a side effect associated with the use of
warfarin; on the other hand, these drugs are not suitable in
cases of poor adherence or in cases of thrombotic recurrence,
notwithstanding therapeutic levels of anticoagulation.10
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Table 1 – Summary of case series, prospective and retrospective studies on the use of new oral anticoagulants in patients
with antiphospholipid syndrome.
Author, year N Primary
APS
Study type Follow-up Previous
arterial event
Triple
positive
Anticoagulant Recurrence
Noel et al., 20155 26 12/26 Retrospective cohort 19 m 12/26 7/26 Rivaroxaban
(n = 15),
dabigatran
(n = 11)
1  (4%)
Sciascia et al., 20156 35 Prospective cohort 10 m 0 ND Rivaroxaban 0
Son et al., 20157 12 8/12 Case series 12 m 2/12 5/12 Rivaroxaban 2 (17%) [2 SLE,
1 previous
arterial event,
1 patient
discontinued
Rivaroxaban 6 d]
Schaefer et al., 20148 3 2/3 Retrospective cohort NA 2/3 1/3 Rivaroxaban
(n = 2), dabigatran
(n = 1)
3  (100%)
Win et al., 20149 3 3/3 Case series NA 2/3 ND Rivaroxaban 2 venous,
1 arterial event
Signorelli et al., 20154 8 8/8 Case series NA 2/8 3/8 Rivaroxaban 6 arterial,
2 venous events
atos
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